000 01552 a2200421 4500
005 20250518033308.0
264 0 _c20190903
008 201909s 0 0 eng d
022 _a1950-6007
024 7 _a10.1016/j.biopha.2019.108725
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAl-Qahtani, Alanod D
245 0 0 _aProduction of "biobetter" variants of glucarpidase with enhanced enzyme activity.
_h[electronic resource]
260 _bBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
_cApr 2019
300 _a108725 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAntimetabolites, Antineoplastic
_xadverse effects
650 0 4 _aCloning, Molecular
650 0 4 _aDrug Design
650 0 4 _aEnzyme Stability
650 0 4 _aEnzyme Therapy
_xmethods
650 0 4 _aMethotrexate
_xadverse effects
650 0 4 _aModels, Molecular
650 0 4 _aNeoplasms
_xdrug therapy
650 0 4 _aPoint Mutation
650 0 4 _aProdrugs
_xadministration & dosage
650 0 4 _aPseudomonas putida
_xgenetics
650 0 4 _aRecombinant Proteins
_xgenetics
650 0 4 _agamma-Glutamyl Hydrolase
_xgenetics
700 1 _aBashraheel, Sara S
700 1 _aRashidi, Fatma B
700 1 _aO'Connor, C David
700 1 _aRomero, Atilio Reyes
700 1 _aDomling, Alexander
700 1 _aGoda, Sayed K
773 0 _tBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
_gvol. 112
_gp. 108725
856 4 0 _uhttps://doi.org/10.1016/j.biopha.2019.108725
_zAvailable from publisher's website
999 _c29574392
_d29574392